Intranasal and sublingual delivery of inactivated polio vaccine (Q40247090)

18 September 2017

Intranasal and sublingual delivery of inactivated polio vaccine (English)

1 reference

18 September 2017

4

Gideon Kersten

1 reference

18 September 2017

Heleen Kraan

1

1 reference

18 September 2017

Peter Soema

series ordinal

2

1 reference

18 September 2017

Jean-Pierre Amorij

series ordinal

3

1 reference

18 September 2017

language of work or name

English

0 references

publication date

8 April 2017

1 reference

18 September 2017

1 reference

18 September 2017

35

1 reference

18 September 2017

20

1 reference

18 September 2017

2647-2653

1 reference

Affordable inactivated poliovirus vaccine: strategies and progress

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Alternative administration routes and delivery technologies for polio vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Dynamic T cell migration program provides resident memory within intestinal epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Control of TH17 cells occurs in the small intestine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Intranasal Vaccination With Salmonella-Derived Serodominant Secreted Effector Protein B Associated With Gas-Filled Microbubbles Partially Protects Against Gut Infection in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Vaccines against mucosal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Identification of an immunodominant T cell epitope on cholera toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Needle-free influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Sublingual vaccination with influenza virus protects mice against lethal viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Development of thermostable lyophilized inactivated polio vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Alternative delivery of a thermostable inactivated polio vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

Induction of compartmentalized B-cell responses in human tonsils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.090

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2017.03.090

1 reference

18 September 2017

1 reference